Alta Semper | Private Equity Firm
Investments that Bring Change
We invest in selected large, diversified, politically stable and fast growing emerging economies
Our completed transactions include the acquisition of Macro Pharmaceuticals, Egypt’s leading medicated cosmeceutical and generics pharma company, an investment into ODM, Morocco’s leading oncology, radiology and diagnostics platform, an investment into MyDawa, East Africa’s leading online pharmacy & telemedicine platform, the acquisition of Allmed, one of Africa’s largest medical device manufacturers and a leading innovator & manufacturer of artificial kidneys and an investment into Nature’s Rule, a MENA-focused leader in nutritional supplements.
Job Creation
Job creation (FTE’s) in portfolio companies
We anchor our impact thesis to UNSDGs, ESG, and Gender Investment Criteria.
Our Portfolio
Headquarters:
Cairo, Egypt
Cosmeceutical and generics pharma
2017
Headquarters:
Casablanca, Morcco
Industry:
Oncology, radiology and diagnostics
Initial Investment Date:
2018
Headquarters:
Nairobi, Kenya
Industry:
E-pharmacy, telemedicine, primary care and diagnostics
Initial Investment Date:
2021
London, United Kingdom
Industry:
Artificial kidneys, dialysis consumables, dialysis machinery and renal pharmaceuticals
Initial Investment Date:
2024
Headquarters: Cairo, Egypt
Headquarters: Casablanca, Morocco
Industry: Oncology, radiology and diagnostics
Initial Investment Date: 2018
Headquarters: Nairobi, Kenya
Industry: E-pharmacy, telemedicine, primary care and diagnostics
Initial Investment Date: 2021
Headquarters: London, United Kingdom
Industry: Blood purification, Artificial Kidneys, Haemodialysis, Haemoconcentration
Initial Investment Date: 2024
Headquarters: Abu Dhabi, United Arab Emirates
Industry: Sports Nutrition, Dietary Supplements
Initial Investment Date: 2026